Key result
The editorial highlights evidence-based lifestyle changes and drugs for obesity and hypertension, noting controversies like maintaining thiazides as first-line therapy despite metabolic syndrome.
This editorial emphasizes the importance of the joint position paper on obesity and hypertension, calling for more research and the elimination of racial/ethnic disparities.
OBJECTIVE: This editorial comments on the recent Obesity Society and American Society of Hypertension joint position paper, justified by the substantial link between obesity and hypertension (HTN). DESIGN AND METHODS: The editorial reviews the expert opinions. Other relevant clinical research is highlighted, such as an obesity paradox. Evidence-based lifestyle changes, drugs, and behavorial modification and newer agents are highlighted. RESULTS: Areas of controversy are noted. Despite the importance of renin angiotensin system blockage, future federal guidelines may maintain thiazides as first choice, even with metabolic syndrome (MetS) and diabetes (DM). Chlorthalidone, 12.5-25 mg, has shown cardiovascular benefit, including with MetS and DM. CONCLUSION: The conclusion calls for more research. However, the identification and elimination of racial/ethnic disparities should be addressed more explicitly. To better understand the obesity-hypertension linkage, curtail costs, and decrease premature disease and death, this excellent position paper is essential.
No takes yet. Share an insight, caveat, or question.
Keith C. Ferdinand (2013) conducted an editorial in Obesity and hypertension. The editorial highlights evidence-based lifestyle changes and drugs for obesity and hypertension, noting controversies like maintaining thiazides as first-line therapy despite metabolic syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: